At the beginning of 2018, QED Therapeutics was launched by Bridge Bio, as a new biotechnology company, focused on precision medicine for FGFR-driven diseases. 1. What are FGFRs? The fibroblast growth factor receptors (FGFRs) regulate important biological processes including cell proliferation … Continue reading →